Hyperinsulinemia may predict diabetes and metabolic syndrome early in young adults

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-05-22 05:15 GMT   |   Update On 2023-05-22 07:29 GMT

Mumbai: Hyperinsulinaemia could be an early biomarker of metabolic disease and progression to metabolic syndrome and diabetes mellitus (DM), a recent study published in Frontiers in Clinical Diabetes and Healthcare has shown."Hyperinsulinaemia in the absence of impaired glucose tolerance and normal haemoglobin A1C (HbA1c) may provide a much earlier indicator for detecting the risk of...

Login or Register to read the full article

Mumbai: Hyperinsulinaemia could be an early biomarker of metabolic disease and progression to metabolic syndrome and diabetes mellitus (DM), a recent study published in Frontiers in Clinical Diabetes and Healthcare has shown.

"Hyperinsulinaemia in the absence of impaired glucose tolerance and normal haemoglobin A1C (HbA1c) may provide a much earlier indicator for detecting the risk of metabolic disease and progression to metabolic syndrome and diabetes mellitus," the researchers wrote.

The researchers note that HbA1c would still be a preferred marker for prediabetes diagnosis for community screening. However, people at high risk, with central adiposity, obesity, a family history of diabetes, or symptomatic (PCOS, acanthosis nigricans) should be tested for insulin resistance and hyperinsulinemia.

Hyperinsulinemia in the absence of impaired glucose tolerance and normal HbA1c indicates prediabetes. Not many Indian studies have focused on hyperinsulinemia, specifically in young adults. Rama A. Vaidya, Kasturba Health Society- Medical Research Center, Mumbai, India, and colleagues aimed to determine whether hyperinsulinemia may be present despite HbA1c being normal in a cross–sectional study.

The study was conducted on young adults and adolescents aged 16-25 living in Mumbai, India. The participants attended various academic institutions and underwent screening as the first step of a clinical trial for studying the efficacy of almond intake in prediabetes.

The study revealed the following findings:

  • Among 1313 young adults, 4.2% of the participants were found to be prediabetic (ADA criteria), and 19.7% of them had HbA1c levels between 5.7%-6.4%.
  • Almost 30.5% had hyperinsulinemia despite normal blood glucose levels and normal HbA1c.
  • Among 533 people with HbA1c<5.7, 10.5% of participants had fasting insulin>15 mIU/L, and a higher percentage (39.4%) had stimulated insulin above 80 mIU/L. These participants had higher mean anthropometric markers than those with normal fasting and stimulated insulin.

To identify prediabetic patients, the researchers measured fasting blood glucose, HbA1c, and two h- glucose-stimulated blood glucose. In the same set of people, they measured fasting insulin and 2- h glucose-stimulated insulin. They determined how many individuals had normal HbA1c, and those who were prediabetic were hyperinsulinemia.

"Our findings revealed that as per the ADA criteria for blood glucose, only 4.2% were prediabetic, whereas 19.9% had HbA1c values in the prediabetic range (5.7% - 6.4%)," the researchers wrote. "That almost one-fifth of the young adults were prediabetic highlights the need to pay attention to this issue."

"Hyperinsulinaemia in the absence of impaired glucose tolerance and normal HbA1c may provide a much earlier indicator of detection for risk of metabolic disease and progression to metabolic syndrome and diabetes," they concluded.

Reference:

Vaidya, R. A., Desai, S., Moitra, P., Salis, S., Agashe, S., Battalwar, R., Mehta, A., Madan, J., Kalita, S., Udipi, S. A., & Vaidya, A. B. (2023). Hyperinsulinemia: An early biomarker of metabolic dysfunction. Frontiers in Clinical Diabetes and Healthcare, 4. https://doi.org/10.3389/fcdhc.2023.1159664


Tags:    
Article Source : Frontiers in Clinical Diabetes and Healthcare

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News